These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16413004)

  • 1. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors.
    Peterson JT
    Cardiovasc Res; 2006 Feb; 69(3):677-87. PubMed ID: 16413004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MMP inhibitors in cardiac diseases: an update.
    Dormán G; Kocsis-Szommer K; Spadoni C; Ferdinandy P
    Recent Pat Cardiovasc Drug Discov; 2007 Nov; 2(3):186-94. PubMed ID: 18221118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial.
    Hudson MP; Armstrong PW; Ruzyllo W; Brum J; Cusmano L; Krzeski P; Lyon R; Quinones M; Theroux P; Sydlowski D; Kim HE; Garcia MJ; Jaber WA; Weaver WD
    J Am Coll Cardiol; 2006 Jul; 48(1):15-20. PubMed ID: 16814643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.
    Baragi VM; Becher G; Bendele AM; Biesinger R; Bluhm H; Boer J; Deng H; Dodd R; Essers M; Feuerstein T; Gallagher BM; Gege C; Hochgürtel M; Hofmann M; Jaworski A; Jin L; Kiely A; Korniski B; Kroth H; Nix D; Nolte B; Piecha D; Powers TS; Richter F; Schneider M; Steeneck C; Sucholeiki I; Taveras A; Timmermann A; Van Veldhuizen J; Weik J; Wu X; Xia B
    Arthritis Rheum; 2009 Jul; 60(7):2008-18. PubMed ID: 19565489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insight into the structural determinants for selective inhibition of matrix metalloproteinases.
    Pirard B
    Drug Discov Today; 2007 Aug; 12(15-16):640-6. PubMed ID: 17706545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery.
    Peterson JT
    Heart Fail Rev; 2004 Jan; 9(1):63-79. PubMed ID: 14739769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can matrix metalloproteinase inhibitors provide a realistic therapy in cardiovascular medicine?
    MacFadyen RJ
    Curr Opin Pharmacol; 2007 Apr; 7(2):171-8. PubMed ID: 17317319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective targeting of matrix metalloproteinase inhibition in post-infarction myocardial remodeling.
    Apple KA; Yarbrough WM; Mukherjee R; Deschamps AM; Escobar PG; Mingoia JT; Sample JA; Hendrick JW; Dowdy KB; McLean JE; Stroud RE; O'Neill TP; Spinale FG
    J Cardiovasc Pharmacol; 2006 Feb; 47(2):228-35. PubMed ID: 16495760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats.
    Renkiewicz R; Qiu L; Lesch C; Sun X; Devalaraja R; Cody T; Kaldjian E; Welgus H; Baragi V
    Arthritis Rheum; 2003 Jun; 48(6):1742-9. PubMed ID: 12794843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of an orally active matrix metalloproteinase inhibitor.
    Yamamoto S; Nakatani S; Ikura M; Sugiura T; Nishita Y; Itadani S; Ogawa K; Ohno H; Takahashi K; Nakai H; Toda M
    Bioorg Med Chem; 2006 Sep; 14(18):6383-403. PubMed ID: 16765051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
    Yang YJ; Zhang X; Zhu WL; Huang Y
    Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Design, synthesis and activity evaluation of novel matrix metalloproteinases inhibitors based on the structure of enzyme].
    Jia H; Guo YS; Ge YY; Wen H; Yang J; Yang XY; Du GH; Yang GZ
    Yao Xue Xue Bao; 2007 Dec; 42(12):1271-81. PubMed ID: 18338640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs.
    Rossello A; Nuti E; Catalani MP; Carelli P; Orlandini E; Rapposelli S; Tuccinardi T; Atkinson SJ; Murphy G; Balsamo A
    Bioorg Med Chem Lett; 2005 May; 15(9):2311-4. PubMed ID: 15837315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function.
    Spinale FG
    Physiol Rev; 2007 Oct; 87(4):1285-342. PubMed ID: 17928585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in MMP inhibitor design.
    Fisher JF; Mobashery S
    Cancer Metastasis Rev; 2006 Mar; 25(1):115-36. PubMed ID: 16680577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tumor metastasis and MMP inhibitor].
    Sato H
    Clin Calcium; 2006 Apr; 16(4):621- 26. PubMed ID: 16582513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.
    Reiter LA; Robinson RP; McClure KF; Jones CS; Reese MR; Mitchell PG; Otterness IG; Bliven ML; Liras J; Cortina SR; Donahue KM; Eskra JD; Griffiths RJ; Lame ME; Lopez-Anaya A; Martinelli GJ; McGahee SM; Yocum SA; Lopresti-Morrow LL; Tobiassen LM; Vaughn-Bowser ML
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3389-95. PubMed ID: 15177439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability.
    Johnson JL; Fritsche-Danielson R; Behrendt M; Westin-Eriksson A; Wennbo H; Herslof M; Elebring M; George SJ; McPheat WL; Jackson CL
    Cardiovasc Res; 2006 Aug; 71(3):586-95. PubMed ID: 16759648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transgenic expression of matrix metalloproteinase-1 inhibits myocardial fibrosis and prevents the transition to heart failure in a pressure overload mouse model.
    Foronjy RF; Sun J; Lemaitre V; D'Armiento JM
    Hypertens Res; 2008 Apr; 31(4):725-35. PubMed ID: 18633185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.